Dr. John McEvoy Burke, MD

Dr. Burke practices at Rocky Mountain Cancer Centers in Aurora, Colorado.

Dr. Burke's NPI, 1801871215, was assigned on December 8, 2005. Dr. Burke graduated from Baylor College of Medicine in 1997. Dr. Burke holds Colorado license DR.0041554.

Dr. Burke's primary practice is Rocky Mountain Cancer Centers, at 1700 S Potomac St, Aurora, CO 80012 in Arapahoe County. The practice phone is (303) 930-7800.

Dr. Burke's primary practice is Rocky Mountain Cancer Centers in Aurora, Colorado. Dr. Burke is also affiliated with HCA HealthONE Aurora. The medical group on file is Rocky Mountain Cancer Centers. Dmand AI also links Dr. Burke to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Burke practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Burke's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Burke is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Burke's licenses on file in 2 states: Colorado and California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Burke treats.

CMS data shows 133,107 Medicare services from Dr. Burke across 83 procedure codes in 2024, for 946 Medicare patients. Medicare paid $2,234,820 for them.

CMS counts 946 Medicare patients who saw Dr. Burke in 2024. The largest group is 65 to 74, with 422 patients. 66% of them have high blood pressure, and 64% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Burke's median patient age at 72, with 51% women.

In 2024, Dr. Burke wrote 2,076 Medicare Part D claims for 278 patients. CMS names the drug for 1,901 of them, across 39 drugs with 11 or more claims each, at $16,360,898 in total drug cost. In 2023, CMS named 1,512 claims across 35 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 73 out of 100 for Dr. Burke for performance year 2024, reported through an alternative payment model (APM). Dr. Burke accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Burke as offering telehealth.

Dmand AI links 191 papers to Dr. Burke, published from 2001 to 2025. 2016 was the busiest year, with 7. The most frequent topics are RNA, Catalytic, Nucleic Acid Conformation and Molecular Sequence Data. Dr. Burke has published most often in Biochemistry. Dr. Burke's most frequent co-authors are Habte Aragaw Yimer, MD, Ian Winchester Flinn, MD and Tycel Jovelle Phillips, MD.

Dmand AI links Dr. Burke to 9 clinical trials, 6 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse and Lymphoma, T-Cell, Peripheral. Seagen Inc. sponsors the most, 4.

CMS Open Payments shows 388 general payments to Dr. Burke from 36 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 65% of the total. Genentech, Inc. paid the most, $161,034. It also lists 37 research payments totaling $46,950 from 2016 to 2025.

Dmand AI lists 1 award for Dr. Burke, most recently CMS Stage 1 2012 in 2012.

Dr. Burke graduated from Baylor College of Medicine in 1997. Dr. Burke is a member of ASCO.

Dr. Burke is in network with 17 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.